TNFRSF4 and cancer: In addition, the anti-CD25 antibody daclizumab[47], the anti-OX40 (CD134) monoclonal antibody[48], and the chemokine receptor 8[49] are in phase I clinical trials, which bring hopes for the treatment of cancer patients.